ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Daewoong Pharmaceutical, Astellas Pharma and Pfizer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Daewoong Pharmaceutical×Astellas Pharma×Pfizer×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Daewoong PharmaceuticalAstellas PharmaPfizer
studies on the registry2249834,072
open to participants now3538146
phase 3 studies under way111399
reach primary completion within a year61491
programswith a study of their own in two years172091+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDaewoong PharmaceuticalAstellas PharmaPfizer
Phase 1

Daewoong Pharmaceutical: 11 of its 17 programs at phase 1

  1. DWJ1622phase 1
  2. DWC202501phase 1
  3. DWJ1511phase 1
  4. DWP212525phase 1
  5. DWRX5003phase 1

and 6 more — sign in to see them all

65%

Astellas Pharma: 2 of its 20 programs at phase 1

  1. ASP2020phase 1
  2. Pan-KRAS Degrader ASP5834phase 1
10%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%
Phase 200%45%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
Phase 3

Daewoong Pharmaceutical: 4 of its 17 programs at phase 3

  1. Enavogliflozinphase 3
  2. prabotulinumtoxin Aphase 3
  3. DWP712phase 3
  4. DWC202518phase 3
24%

Astellas Pharma: 4 of its 20 programs at phase 3

  1. fezolinetantphase 3
  2. setidegrasibphase 3
  3. emaretamigphase 3
  4. gilteritinibphase 3
20%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
Approved, new studies

Daewoong Pharmaceutical: 2 of its 17 programs at approved, new studies

  1. fexuprazanapproved, new study
  2. luprolide acetate gel depotapproved, new study
12%

Astellas Pharma: 5 of its 20 programs at approved, new studies

  1. zolbetuximabapproved, new study
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study
  4. avacincaptad pegolapproved, new study
  5. Sirolimusapproved, new study
25%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Daewoong Pharmaceutical2 readouts · 0 phase 3·

Daewoong Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion

  1. DWP212525phase 1 · Dec 30 · NCT06736587
··

Daewoong Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. olaparibphase 1 · Mar 0 · NCT07371104
·······
Astellas Pharma9 readouts · 2 phase 3·

Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Cphase 2 · Dec 30 · NCT06792435
  2. enfortumab vedotinapproved, new study · Dec 31 · NCT06862219
  3. zolbetuximabapproved, new study · Dec 31 · NCT06396091
···

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 3 · Apr 30 · NCT07783282
·

Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. avacincaptad pegolapproved, new study · Jun 30 · NCT06970665
···

Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion

  1. Methylprednisolonephase 2 · Oct 31 · NCT07052929
  2. Prednisolonephase 2 · Oct 31 · NCT07052929
  3. Sirolimusapproved, new study · Oct 31 · NCT07052929
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Daewoong Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Astellas Pharma

New programs 1

  • ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 21 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionDaewoong PharmaceuticalAstellas PharmaPfizer
Carcinoma, Non-Small-Cell Lungall three · compare here

Daewoong Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. olaparibphase 1

Their studies: Daewoong Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 4 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Daewoong Pharmaceutical in Breast Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Daewoong Pharmaceutical’s studies of Breast Neoplasms in search

Astellas Pharma in Breast Neoplasms: 2 programs

  1. enzalutamideapproved, new study
  2. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Prostatic Neoplasmsall three · compare here

Daewoong Pharmaceutical in Prostatic Neoplasms: 2 programs

  1. olaparibphase 1
  2. luprolide acetate gel depotapproved, new study

Their studies: Daewoong Pharmaceutical’s studies of Prostatic Neoplasms in search

Astellas Pharma in Prostatic Neoplasms: 4 programs

  1. fezolinetantphase 3
  2. Prednisolonephase 2
  3. ASP5541phase 2
  4. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Prostatic Neoplasms in search

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Neoplasmsall three · compare here

Daewoong Pharmaceutical in Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Daewoong Pharmaceutical’s studies of Neoplasms in search

Astellas Pharma in Neoplasms: 3 programs

  1. setidegrasibphase 3
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Neoplasms in search

Pfizer in Neoplasms: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Obesity2 of 3 · compare here

Daewoong Pharmaceutical in Obesity: 1 program

  1. DWRX5003phase 1

Their studies: Daewoong Pharmaceutical’s studies of Obesity in search

–

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Renal Insufficiency2 of 3 · compare here–

Astellas Pharma in Renal Insufficiency: 2 programs

  1. fezolinetantphase 3
  2. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Non-Muscle Invasive Bladder Neoplasms2 of 3 · compare here–

Astellas Pharma in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. enfortumab vedotinapproved, new study

Their studies: Astellas Pharma’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Asthma2 of 3 · compare here–

Astellas Pharma in Asthma: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Asthma in search

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Diabetes Mellitus, Type 22 of 3 · compare here

Daewoong Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. Enavogliflozinphase 3
  2. DWC202518phase 3

Their studies: Daewoong Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

–

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Migraine Disorders2 of 3 · compare here

Daewoong Pharmaceutical in Migraine Disorders: 1 program

  1. prabotulinumtoxin Aphase 3

Their studies: Daewoong Pharmaceutical’s studies of Migraine Disorders in search

–

Pfizer in Migraine Disorders: 2 programs

  1. zavegepantphase 3
  2. rimegepantapproved, new study

Their studies: Pfizer’s studies of Migraine Disorders in search

Stomach Neoplasms2 of 3 · compare here–

Astellas Pharma in Stomach Neoplasms: 1 program

  1. zolbetuximabapproved, new study

Their studies: Astellas Pharma’s studies of Stomach Neoplasms in search

Pfizer in Stomach Neoplasms: 2 programs

  1. tivunatamigphase 3
  2. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Adenocarcinoma Of Esophagus2 of 3 · compare here–

Astellas Pharma in Adenocarcinoma Of Esophagus: 1 program

  1. zolbetuximabapproved, new study

Their studies: Astellas Pharma’s studies of Adenocarcinoma Of Esophagus in search

Pfizer in Adenocarcinoma Of Esophagus: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Adenocarcinoma Of Esophagus in search

Show all 21

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetDaewoong PharmaceuticalAstellas PharmaPfizer
CD3E–emaretamigruleelranatamabrule
KRAS–Pan-KRAS Degrader ASP5834rulePan-KRAS Inhibitor PF-07985045rule
A target, or a pathogen for a vaccine, known for: Daewoong Pharmaceutical 3 of 17 · Astellas Pharma 12 of 20 · Pfizer 67 of 91 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).